Table A5.

Multivariate Analysis Including Post-Treatment SUV_peak (institutional read) as a Variable

Parameter	Hazard Ratio	95% CI	P
Age (years): continuous	1.021	0.998 to 1.044	.079
Sex: female v male	1.164	0.781 to 1.735	.456
Performance status: ambulatory, capable of light work v fully active	1.328	0.911 to 1.937	.140
Clinical stage
IIIA v IIB	0.828	0.339 to 2.026	.680
IIIB v IIB	0.985	0.395 to 2.455	.974
Radiotherapy dose (Gy): continuous	0.990	0.949 to 1.033	.642
Chemotherapy regimen
Cisplatin + etoposide v carboplatin + paclitaxel	1.062	0.594 to 1.898	.839
Other v carboplatin + paclitaxel	1.138	0.749 to 1.729	.544
Post-treatment SUVpeak: continuous	1.087	1.014 to 1.166	.020

NOTE. To assess the overall performance of the model, the C statistic was computed using the approach developed by Uno et al (Uno H, et al: Stat Med 30:1105-1117, 2011). It is 0.579 under the above model. For comparison, the C statistic is 0.573 when post-treatment SUV_peak is excluded from the model.

Abbreviation: SUV_peak, peak standardized uptake value.